[ad_1]
Clinical-stage biotechnology will derive emerging non-genetically modified hematopoietic stem cells and their derived immune cell therapies
BIO CEO and Investor Conference 2024
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) — Cell BioEngines, Inc., a biotechnology company focused on developing “off-the-shelf” “non-genetically modified” hematopoietic stem cells and their derived immune cell therapies for cancer patients, today Announced that Cell BioEngines Founder and CEO Dr. Ajay Vishwakarma will speak at the BIO CEO and Investor Conference on Monday, February 26, 2024 at 2:00 pm ET.
“We are pleased to receive free registration tickets sponsored by the New York City Economic Development Corporation (NYCEDC) under the Emerging Innovators Track,” said Ajay Vishwakarma, DMD, MS, MBA. “At the BIO CEO and Investor Conference, I will highlight Cell BioEngines’ latest advances in novel stem cell and immune cell therapies for difficult-to-treat hematological and solid cancers, ongoing pipeline progress, clinical trial updates, and anticipated Progress. Milestones,” he added.
Details of the speech are as follows:
host: Dr. Ajay Vishwakarma, Founder and CEO, Cell BioEngines
date: Monday, February 26, 2024 at 2:00 pm ET
Place: Plymouth Room at New York Marriott Marquis, NY
Registration: here
Add to calendar: here
The BIO CEO Conference has been held for 26 years and is one of the largest investor conferences in the life sciences industry. Cell BioEngines will be available for in-person and virtual collaboration meetings. Those interested in arranging meetings can do so through the BIO one-to-one cooperation system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering.
About Cell BioEngines
Cell BioEngines, Inc. is a clinical-stage biotechnology company focused on developing “off-the-shelf” allogeneic cell therapies as “drugs” to transform all cancers into curable diseases.The company leverages its proprietary technology Dry–Space™ Platform technology to produce clinical-grade cells with economies of scale. The company’s versatile platform and pipeline enable them to pursue a broad pipeline of cell and gene therapy product candidates in therapeutic areas with high clinical and commercial potential.
For more information about Cell BioEngines, as well as Dr. Vishwakarma’s presentation and company updates, please visit www.cellbioengines.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/410c8a90-eda5-4537-bae3-dbb64dd7a610
CONTACT: Contact Mark Joubert., J.D. Chief Legal Officer Cell BioEngines, Inc info@cellbioengines.com
[ad_2]
Source link